Donald E. Bobo Jr., Edwards Lifesciences’ corporate VP of strategy and corporate development, will retire by mid-2027, according to an SEC filing posted on Aug. 28.
The Irvine, California–based structural heart devices company plans to promptly begin a search for Bobo’s successor, with a transition expected next year. Bobo will continue to consult with the company through the end of 2027.
According to his LinkedIn page, Bobo has been focused on “driving advancements in the dynamic field of medical technology and life sciences.” He said: “With 35+ years of experience in executive leadership, strategic management, business development, and innovation, I’m passionate about leading teams to achieve meaningful goals and deliver innovative solutions that positively impact patients.”
Bobo’s LinkedIn page says he joined Edwards Lifesciences in 1995.
Edwards Lifesciences outlined a strategy late last year for sustained growth momentum, saying it remains “uniquely positioned” across its leading therapies for core structural heart conditions, including aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases. In addition, the company seeks to expand into emerging opportunities like aortic regurgitation (AR) and structural heart failure.
The company saw 13.6% sales growth in its second quarter and raised revenue guidance, with EW shares up more than 6% to more than $90 apiece so far this year.
